Patisiran Sodium is an RNA interference therapeutic agent indicated for the treatment of polyneuropathy in patients with hereditary transthyretin-mediated amyloidosis (hATTR). By silencing mutant transthyretin… Read more
Patisiran Sodium is an RNA interference therapeutic agent indicated for the treatment of polyneuropathy in patients with hereditary transthyretin-mediated amyloidosis (hATTR). By silencing mutant transthyretin mRNA, this drug effectively reduces the production of toxic transthyretin protein associated with the disease. To support rigorous analytical requirements, this category offers a comprehensive selection of high-quality reference standards, including the active pharmaceutical ingredient, relevant pharmacopeial and non-pharmacopeial impurities, and stable isotope-labelled compounds. These materials are essential for pharmaceutical laboratories conducting impurity profiling, method validation, and ongoing quality control of oligonucleotide formulations. Utilizing these specialized standards ensures accurate identification and quantification during stability testing and release assays, enabling strict adherence to regulatory compliance throughout the development and manufacturing lifecycle of this complex therapeutic.